Arginine-vasopressin V1 but not V2 receptor antagonism modulates infarct volume, brain water content, and aquaporin-4 expression following experimental stroke

Xiaoqin Liu, Shin Nakayama, Mahmood Amiry-Moghaddam, Ole Petter Ottersen, Anish Bhardwaj

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Background: Aquaporin-4 (AQP4) plays an important role in the evolution of ischemia-evoked cerebral edema. Experimental studies have also demonstrated anti-edema effects of arginine-vasopressin (AVP) antagonists. In a well-characterized murine model of ischemic stroke, we tested the hypotheses that treatment with selective AVP V1 but not V2 receptor antagonist (1) attenuates injury volume and ischemia-evoked cerebral edema; and (2) modulates ischemia-evoked AQP4 expression. Methods: Isoflurane-anesthetized adult male C57bl/6 mice were subjected to 60 min of middle cerebral artery occlusion (MCAO) by the intraluminal suture technique. Adequacy of MCAO and reperfusion was monitored with laser-Doppler flowmetry over the ipsilateral parietal cortex. Mice were treated with intracerebroventricular injection of selective AVP V1 and V2 receptor antagonist or control vehicle (0.9% saline). Infarct volume (tetrazolium staining), cerebral edema (wet-to-dry ratios) and AQP4 protein expression (immunoblotting) were determined in different treatment groups in separate sets of experiments at 24 h of reperfusion. Results: Infarct volume (percentage of contralateral structure; mean ± SEM) was significantly attenuated in mice treated with 500 ng V1 receptor antagonist as well as at a dose of 1000 ng compared to controls. However, there was no difference in infarct volume following treatment with 1000 ng V2 antagonist as compared to controls. Water content in the ischemic hemisphere was significantly attenuated with V1 receptor antagonist (1000 ng) but not with V2 receptor antagonist as compared to controls. Treatment with AVP V1 receptor antagonist (1000 ng) but not V2 receptor antagonist, significantly upregulated AQP4 protein expression (% β-actin) compared to saline-treated mice in ipsilateral (ischemic) cerebral cortex. Conclusions: These data demonstrate that following experimental stroke AVP V1 receptor antagonism: (1) attenuates injury volume and ischemia-evoked cerebral edema; (2) modulates AQP4 expression; and (3) may serve as an important therapeutic target for neuroprotection and ischemia-evoked cerebral edema.

Original languageEnglish (US)
Pages (from-to)124-131
Number of pages8
JournalNeurocritical Care
Volume12
Issue number1
DOIs
StatePublished - Feb 2010
Externally publishedYes

Fingerprint

Aquaporin 4
Vasopressin Receptors
Arginine Vasopressin
Stroke
Water
Brain
Brain Edema
Ischemia
Middle Cerebral Artery Infarction
Reperfusion
Therapeutics
Suture Techniques
Parietal Lobe
Laser-Doppler Flowmetry
Isoflurane
Wounds and Injuries
Immunoblotting
Cerebral Cortex
Actins

Keywords

  • Aquaporins
  • Arginine-vasopressin
  • Cerebral edema
  • Focal cerebral ischemia
  • Infarct
  • Stroke

ASJC Scopus subject areas

  • Clinical Neurology
  • Critical Care and Intensive Care Medicine

Cite this

Arginine-vasopressin V1 but not V2 receptor antagonism modulates infarct volume, brain water content, and aquaporin-4 expression following experimental stroke. / Liu, Xiaoqin; Nakayama, Shin; Amiry-Moghaddam, Mahmood; Ottersen, Ole Petter; Bhardwaj, Anish.

In: Neurocritical Care, Vol. 12, No. 1, 02.2010, p. 124-131.

Research output: Contribution to journalArticle

@article{96fc0d1e10b04ab99e9af5c34547ca95,
title = "Arginine-vasopressin V1 but not V2 receptor antagonism modulates infarct volume, brain water content, and aquaporin-4 expression following experimental stroke",
abstract = "Background: Aquaporin-4 (AQP4) plays an important role in the evolution of ischemia-evoked cerebral edema. Experimental studies have also demonstrated anti-edema effects of arginine-vasopressin (AVP) antagonists. In a well-characterized murine model of ischemic stroke, we tested the hypotheses that treatment with selective AVP V1 but not V2 receptor antagonist (1) attenuates injury volume and ischemia-evoked cerebral edema; and (2) modulates ischemia-evoked AQP4 expression. Methods: Isoflurane-anesthetized adult male C57bl/6 mice were subjected to 60 min of middle cerebral artery occlusion (MCAO) by the intraluminal suture technique. Adequacy of MCAO and reperfusion was monitored with laser-Doppler flowmetry over the ipsilateral parietal cortex. Mice were treated with intracerebroventricular injection of selective AVP V1 and V2 receptor antagonist or control vehicle (0.9{\%} saline). Infarct volume (tetrazolium staining), cerebral edema (wet-to-dry ratios) and AQP4 protein expression (immunoblotting) were determined in different treatment groups in separate sets of experiments at 24 h of reperfusion. Results: Infarct volume (percentage of contralateral structure; mean ± SEM) was significantly attenuated in mice treated with 500 ng V1 receptor antagonist as well as at a dose of 1000 ng compared to controls. However, there was no difference in infarct volume following treatment with 1000 ng V2 antagonist as compared to controls. Water content in the ischemic hemisphere was significantly attenuated with V1 receptor antagonist (1000 ng) but not with V2 receptor antagonist as compared to controls. Treatment with AVP V1 receptor antagonist (1000 ng) but not V2 receptor antagonist, significantly upregulated AQP4 protein expression ({\%} β-actin) compared to saline-treated mice in ipsilateral (ischemic) cerebral cortex. Conclusions: These data demonstrate that following experimental stroke AVP V1 receptor antagonism: (1) attenuates injury volume and ischemia-evoked cerebral edema; (2) modulates AQP4 expression; and (3) may serve as an important therapeutic target for neuroprotection and ischemia-evoked cerebral edema.",
keywords = "Aquaporins, Arginine-vasopressin, Cerebral edema, Focal cerebral ischemia, Infarct, Stroke",
author = "Xiaoqin Liu and Shin Nakayama and Mahmood Amiry-Moghaddam and Ottersen, {Ole Petter} and Anish Bhardwaj",
year = "2010",
month = "2",
doi = "10.1007/s12028-009-9277-x",
language = "English (US)",
volume = "12",
pages = "124--131",
journal = "Neurocritical Care",
issn = "1541-6933",
publisher = "Humana Press",
number = "1",

}

TY - JOUR

T1 - Arginine-vasopressin V1 but not V2 receptor antagonism modulates infarct volume, brain water content, and aquaporin-4 expression following experimental stroke

AU - Liu, Xiaoqin

AU - Nakayama, Shin

AU - Amiry-Moghaddam, Mahmood

AU - Ottersen, Ole Petter

AU - Bhardwaj, Anish

PY - 2010/2

Y1 - 2010/2

N2 - Background: Aquaporin-4 (AQP4) plays an important role in the evolution of ischemia-evoked cerebral edema. Experimental studies have also demonstrated anti-edema effects of arginine-vasopressin (AVP) antagonists. In a well-characterized murine model of ischemic stroke, we tested the hypotheses that treatment with selective AVP V1 but not V2 receptor antagonist (1) attenuates injury volume and ischemia-evoked cerebral edema; and (2) modulates ischemia-evoked AQP4 expression. Methods: Isoflurane-anesthetized adult male C57bl/6 mice were subjected to 60 min of middle cerebral artery occlusion (MCAO) by the intraluminal suture technique. Adequacy of MCAO and reperfusion was monitored with laser-Doppler flowmetry over the ipsilateral parietal cortex. Mice were treated with intracerebroventricular injection of selective AVP V1 and V2 receptor antagonist or control vehicle (0.9% saline). Infarct volume (tetrazolium staining), cerebral edema (wet-to-dry ratios) and AQP4 protein expression (immunoblotting) were determined in different treatment groups in separate sets of experiments at 24 h of reperfusion. Results: Infarct volume (percentage of contralateral structure; mean ± SEM) was significantly attenuated in mice treated with 500 ng V1 receptor antagonist as well as at a dose of 1000 ng compared to controls. However, there was no difference in infarct volume following treatment with 1000 ng V2 antagonist as compared to controls. Water content in the ischemic hemisphere was significantly attenuated with V1 receptor antagonist (1000 ng) but not with V2 receptor antagonist as compared to controls. Treatment with AVP V1 receptor antagonist (1000 ng) but not V2 receptor antagonist, significantly upregulated AQP4 protein expression (% β-actin) compared to saline-treated mice in ipsilateral (ischemic) cerebral cortex. Conclusions: These data demonstrate that following experimental stroke AVP V1 receptor antagonism: (1) attenuates injury volume and ischemia-evoked cerebral edema; (2) modulates AQP4 expression; and (3) may serve as an important therapeutic target for neuroprotection and ischemia-evoked cerebral edema.

AB - Background: Aquaporin-4 (AQP4) plays an important role in the evolution of ischemia-evoked cerebral edema. Experimental studies have also demonstrated anti-edema effects of arginine-vasopressin (AVP) antagonists. In a well-characterized murine model of ischemic stroke, we tested the hypotheses that treatment with selective AVP V1 but not V2 receptor antagonist (1) attenuates injury volume and ischemia-evoked cerebral edema; and (2) modulates ischemia-evoked AQP4 expression. Methods: Isoflurane-anesthetized adult male C57bl/6 mice were subjected to 60 min of middle cerebral artery occlusion (MCAO) by the intraluminal suture technique. Adequacy of MCAO and reperfusion was monitored with laser-Doppler flowmetry over the ipsilateral parietal cortex. Mice were treated with intracerebroventricular injection of selective AVP V1 and V2 receptor antagonist or control vehicle (0.9% saline). Infarct volume (tetrazolium staining), cerebral edema (wet-to-dry ratios) and AQP4 protein expression (immunoblotting) were determined in different treatment groups in separate sets of experiments at 24 h of reperfusion. Results: Infarct volume (percentage of contralateral structure; mean ± SEM) was significantly attenuated in mice treated with 500 ng V1 receptor antagonist as well as at a dose of 1000 ng compared to controls. However, there was no difference in infarct volume following treatment with 1000 ng V2 antagonist as compared to controls. Water content in the ischemic hemisphere was significantly attenuated with V1 receptor antagonist (1000 ng) but not with V2 receptor antagonist as compared to controls. Treatment with AVP V1 receptor antagonist (1000 ng) but not V2 receptor antagonist, significantly upregulated AQP4 protein expression (% β-actin) compared to saline-treated mice in ipsilateral (ischemic) cerebral cortex. Conclusions: These data demonstrate that following experimental stroke AVP V1 receptor antagonism: (1) attenuates injury volume and ischemia-evoked cerebral edema; (2) modulates AQP4 expression; and (3) may serve as an important therapeutic target for neuroprotection and ischemia-evoked cerebral edema.

KW - Aquaporins

KW - Arginine-vasopressin

KW - Cerebral edema

KW - Focal cerebral ischemia

KW - Infarct

KW - Stroke

UR - http://www.scopus.com/inward/record.url?scp=76649118107&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76649118107&partnerID=8YFLogxK

U2 - 10.1007/s12028-009-9277-x

DO - 10.1007/s12028-009-9277-x

M3 - Article

C2 - 19806476

AN - SCOPUS:76649118107

VL - 12

SP - 124

EP - 131

JO - Neurocritical Care

JF - Neurocritical Care

SN - 1541-6933

IS - 1

ER -